0.8723USD8.900 SEK · STO+2.53%Mkt Cap: 7.61M USDP/E: —2d ago
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.…
ANNXAnnexin Pharmaceuticals AB (publ)0.8723USD+2.53%
Annexin Pharmaceuticals (STO: ANNX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 8.900 SEK on 20 November 2026, down 66.8% over 52 weeks. Its 52-week range is 6.240 SEK to 27.40 SEK: the price is 67.5% below the high and 42.6% above the low.
Its market capitalisation is 77.59M SEK.
Annexin Pharmaceuticals reports return on equity of -148.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 14.44M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.